Sulforhodamine 101 selectively labels human astrocytoma cells in an animal model of glioblastoma

Authors

• Joseph F. Georges, Division of Neuroscience, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA; Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Road, Phoenix, AZ 85013, USA; Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA.
• Nikolay L. Martirosyan, Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Road, Phoenix, AZ 85013, USA.Follow
• Jennifer Eschbacher, Division of Neuropathology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.Follow
• Joshua Nichols, College of Medicine, University of Arizona, Phoenix, AZ, USA.
• Maya Tissot, Division of Neuroscience, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
• Mark C. Preul, Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Road, Phoenix, AZ 85013, USA.
• Burt Feuerstein, College of Medicine, University of Arizona, Phoenix, AZ, USA.
• Trent Anderson, College of Medicine, University of Arizona, Phoenix, AZ, USA.
• Robert F. Spetzler, Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Road, Phoenix, AZ 85013, USA.
• Peter Nakaji, Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Road, Phoenix, AZ 85013, USA. Electronic address: Neuropub@dignityhealth.org.

Document Type

Article

Abstract

Sulforhodamine 101 (SR101) is a useful tool for immediate staining of astrocytes. We hypothesized that if the selectivity of SR101was maintained in astrocytoma cells, it could prove useful for glioma research. Cultured astrocytoma cells and acute slices from orthotopic human glioma (n=9) and lymphoma (n=6) xenografts were incubated with SR101 and imaged with confocal microscopy. A subset of slices (n=18) were counter-immunostained with glial fibrillary acidic protein and CD20 for stereological assessment of SR101 co-localization. SR101 differentiated astrocytic tumor cells from lymphoma cells. In acute slices, SR101 labeled 86.50% (±1.86; p<0.0001) of astrocytoma cells and 2.19% (±0.47; p<0.0001) of lymphoma cells. SR101-labeled astrocytoma cells had a distinct morphology when compared with in vivo astrocytes. Immediate imaging of human astrocytoma cells in vitro and in ex vivo rodent xenograft tissue labeled with SR101 can identify astrocytic tumor cells and help visualize the tumor margin. These features are useful in studying astrocytoma in the laboratory and may have clinical applications.

Medical Subject Headings

Animals; Astrocytoma (pathology); Brain Neoplasms (diagnosis); Cell Line, Tumor; Coloring Agents; Disease Models, Animal; Glioblastoma (diagnosis); Humans; Male; Rats; Rhodamines; Xenograft Model Antitumor Assays (methods)

Publication Date

5-1-2014

Publication Title

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

E-ISSN

1532-2653

Volume

21

Issue

5

First Page

846

Last Page

51

PubMed ID

24666692

Digital Object Identifier (DOI)

10.1016/j.jocn.2014.02.007

Recommended Citation

Georges, Joseph F.; Martirosyan, Nikolay L.; Eschbacher, Jennifer; Nichols, Joshua; Tissot, Maya; Preul, Mark C.; Feuerstein, Burt; Anderson, Trent; Spetzler, Robert F.; and Nakaji, Peter, "Sulforhodamine 101 selectively labels human astrocytoma cells in an animal model of glioblastoma" (2014). Neurosurgery. 1718.
https://scholar.barrowneuro.org/neurosurgery/1718